The results reveal a novel mechanism that pharmacological inhibition of PDE1 attenuates human 44 DSM excitability and contractility by activating BK channels via a PKA-dependent mechanism.
Overactive bladder (OAB), one of the most common forms of lower urinary tract 50 dysfunction, is often associated with increased detrusor smooth muscle (DSM) contractility (2). 51 Currently, the primary option for pharmacological treatment of OAB is antagonists of G-protein-52 coupled muscarinic acetylcholine (ACh) receptors (mAChRs) (1, 3). However, mAChR 53 antagonists have limited efficacy and undesirable side effects for many OAB patients (1, 3 (8, 12, 16, 27, 28 enzymatic digestion using procedures previously described (12, 26) . Briefly, 1-2 DSM strips free 108 of mucosa were incubated at 37°C for ~20 min in 2 ml Ca 2+ -free dissection solution 109 supplemented with 1 mg/ml bovine serum albumin (BSA), 1 mg/ml papain, and 1 mg/ml DL- supplemented with 1 mg/ml BSA, 0.5 mg/ml collagenase, 0.5 mg/ml trypsin inhibitor, 100 μM 115 CaCl 2 and incubated at 37°C for 7-12 min followed by three washouts with fresh dissection Fig. 1A-B) . The inhibition of PDE1 increases the cellular cAMP levels and 177 consequently activates PKA (28). H-89 (10 µM), a PKA inhibitor, abolished the potentiating 178 effect of 8MM-IBMX on TBKCs (Fig. 1A) . In the presence of 8MM-IBMX, H-89 (10 µM) 
Discussion

218
The current study revealed a novel mechanism by which PDE1 regulates human DSM 219 function. The data demonstrated that the inhibition of PDE1 increases BK channel currents via 220 PKA-mediated signaling pathways, leading to a decrease in human DSM excitability and 221 contractility (Fig. 6) . This is the first study indicating that the constitutively active PDE1 plays a 222 key role in maintaining human DSM contractility. increased TBKCs in a PKA-dependent manner in human DSM cells (Fig. 1) (Figs. 1 and 3) . We previously reported that selective PDE1 231 inhibition hyperpolarizes human DSM cell membrane potential (28). In the current study, we 232 further revealed that this hyperpolarizing effect was PKA-dependent (Fig. 3) . These results
233
indicate that PDE1 is an important component of the cAMP/PKA signaling pathways which 234 critically regulates human DSM excitability (Fig. 6) (Fig. 6) PDE1 and increases the hydrolysis of cAMP to further suppress PKA activity (Fig. 6) (6) . A 258 decrease in basal PKA activity significantly attenuates BK channels in DSM cells (19, 27) . 259 However, this concept needs further investigation as it is particularly important to also study the 260 enzymatic kinetics of PDE1 regarding its regulation by mAChRs in human DSM. In agreement 261 with this concept, the activation of mAChR 3 suppresses BK channels in human DSM cells, 262 which is consistent with our previous findings (17, 18). More importantly, the inhibition of 263 PDE1 substantially recovered TBKC activity, which was suppressed by mAChR 3 activation.
264
These results support the concept for a potential functional interaction between PDE1 and 265 mAChRs in human DSM (Fig. 2) (6) . The activation of PDE1 by mAChR 3 -mediated Ca (Fig. 6) . Thus, combination therapies, consisting of PDE1 (Fig. 4) . Furthermore, EFS-280 induced contractions, which are primarily caused by neuronal ACh release, were also 281 significantly attenuated by PDE1 inhibition (Fig. 5) .
282
In conclusion, our data provide mechanistic evidence that pharmacological inhibition of 283 PDE1 may represent a novel therapeutic approach for the treatment of OAB by attenuating DSM 284 excitability and contractility through PKA-dependent BK channel activation (Fig. 6) 
